Two-Drug combo aims to shrink tumors before surgery
NCT ID NCT07160647
Summary
This study is testing whether two immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery can help shrink tumors in people with locally advanced rectal cancer that has specific genetic features. The main goal is to see if the treatment completely eliminates cancer cells in the surgical specimen. Researchers will also track side effects, survival rates, and quality of life over three years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMMR/MSI-H-TYPE RECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang, 310016, China
Conditions
Explore the condition pages connected to this study.